OBJECTIVE: Local unresectable recurrence of @entity421 is one of the most challenging @entity5 to treat. @entity2101 ( @entity2101 ) is a new, noninvasive technique with potential to ablate and inactivate @entity5 . Treatment of @entity5 with @entity2101 has been reported. In this study, we assessed safety and efficacy of @entity2101 in treating local unresectable recurrence of @entity421 . METHODS: We performed a retrospective analysis of 27 @entity1 who had local unresectable recurrence of @entity421 from 2006 to 2010. Changes of biochemical markers and @entity158 rating, response rate, disease control rate, @entity66 progression-free survival, progression-free survival (PFS) and overall survival (OS) were used to evaluate efficacy of @entity2101 treatment. RESULTS: @entity2101 resulted in a significant change in alkaline phosphatase and @entity880 dehydrogenase and a remarkably relief in @entity158 rating, without severe side effects. According to MRI examination 4-6 weeks after @entity2101 treatment, 2 (7.4%) @entity1 had complete response (CR), 12 (44.4%) had partial response (PR), 9 (33.3%) had @entity66 ( @entity66 ) and 4 (14.8%) had @entity74 ( @entity74 ). The response rate was 51.8% and the @entity66 control rate was 85.2%. The 1-, 2-, and 3-year @entity66 control rates were 59.2%, 40.7% and 33.1%, respectively. The median @entity66 progression-free time was 14 months, the median progression-free time was 13 months and the median over-all survival time was 21 months. @entity1 without @entity358 had a better @entity66 control rate at 1-,2-,3-year and a longer @entity66 progression-free time, progression-free time, over-all survival time than @entity1 with @entity358 . CONCLUSION: @entity2101 is a safe and noninvasive treatment for local unresectable recurrence of @entity421 , with good local control and without severe complications.

XXXX : Noninvasive treatment for local unresectable recurrence of @entity421 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'local disease', 'SD'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors', 'solid tumors'] @entity421 :: ('MESH:D012516', 'Disease') :: ['osteosarcoma'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary metastasis'] @entity2101 :: ('MESH:C538394', 'Disease') :: ['High-intensity focused ultrasound', 'HIFU'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactic acid'] @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progression disease']
@entity2101 :: (MESH:C538394,Disease) :: ['High-intensity focused ultrasound']
